PE-22-28

Spadin analog / TREK-1 inhibitor studied in depression and neurogenesis models.

Also known as

Spadin analog · TREK-1 inhibitor peptide · PE 22-28

Overview

PE-22-28 is a spadin-related peptide analog studied as a TREK-1 potassium-channel inhibitor in depression and neurogenesis models. Literature explores antidepressant-like and hippocampal plasticity endpoints in preclinical systems.

It sits on cognitive/neuro catalogs despite cosmetic-section misfiling in some lists. Left Turn Adventures supplies this compound for laboratory and research use only.

Proven benefits

Note: Preclinical / literature endpoints for labs — not established human treatment benefits. Not a protocol.

• TREK-1 inhibition endpoints in neural models

• • Antidepressant-like behavioral markers where studied

• • Neurogenesis and hippocampal plasticity readouts

• • Spadin-analog channel pharmacology

• • Comparative mood-research peptide framing

Results timeline

Note: Illustrative research-observation windows — not a clinical schedule. No dosing.

• Week 1–2: Early signaling and behavioral endpoints in acute neuro models; exposure establishing.

• • Week 3–4: Clearer cognitive, stress, or neuroprotective markers in short research windows.

• • Month 2–3: More stable memory, focus, or neuroplasticity-related endpoints in extended designs.

• • Month 3–6: Sustained neuro and aging-adjacent observations where longer protocols are used.

The catalog, not a clinic

For laboratory and research use only. Not for human or animal consumption. Products are sold solely to qualified researchers and licensed laboratories. No dosing or reconstitution on this page.